BPC-157 (Pentadecapeptide)

The Zagreb Research Programme

UKPWritten & reviewed by William Heath · Editor, UK Peptides research library2 min readLast reviewed 2026-08-234 cited sources

The short answer

Most BPC-157 research originates from a group at the University of Zagreb led by Predrag Sikirić, spanning three decades and covering gastrointestinal, musculoskeletal and vascular models. That concentration gives the literature depth and limits its independence.

Key facts

Institution
University of Zagreb
Principal investigator
Predrag Sikirić
Span
Roughly three decades
Model organism
Predominantly rat
Range
GI, tendon, ligament, vascular, ocular
Clinical work
PL-14736 for IBD

The scope of the programme

The Zagreb group has published on BPC-157 across an unusually wide range of models, gastrointestinal lesions, fistula healing, tendon and ligament repair, blood vessel effects, and more recently ocular applications. Sikirić's 2011 review in Current Pharmaceutical Design, 2020 work on fistula healing and 2023 paper in Pharmaceuticals map that breadth.

What sustained programmes provide

Continuity and accumulated method. A group that has worked on one molecule for thirty years knows its handling, its assays and its failure modes in ways that cannot be reconstructed from papers. That depth is valuable and it is why the Zagreb literature is the starting point for anyone studying this compound.

Research material referenced

BPC-157 5mg, third-party HPLC tested

Buy BPC-157 · £16.95

The breadth question

A compound reported active in gastrointestinal, musculoskeletal, vascular and ocular models is either pleiotropic or is being tested by a group with a strong prior. Both are possible and they are not mutually exclusive. Breadth of reported activity is a reason for interest and also a reason for caution, because compounds that appear to work in everything have a poor historical record.

Why independent replication matters here specifically

Shared reagents, shared assays and shared assumptions propagate through a single group's output in ways that are invisible in any individual paper. Replication by unconnected investigators is what tests for that. For BPC-157 the independent literature is thinner than the total volume suggests, which is the single most useful caveat to carry into reading it.

The trial as an independence test

The Phase 2 trial now recruiting, NCT07437547, is sponsored by Hudson Biotech rather than by the original research group. A randomised, double-blind, placebo-controlled trial run by an unconnected sponsor is exactly the kind of test the literature has lacked, and its result (whichever way it goes) will be more informative than any further preclinical work.

Frequently asked questions

Who is Predrag Sikirić?

The researcher at the University of Zagreb who has led the BPC-157 research programme across roughly three decades and authored much of its literature.

Does concentrated authorship invalidate the work?

No. It means the evidence is less independent than the volume implies, which is a standard consideration in appraising any literature.

Why does the current trial matter?

It is sponsored by an unconnected party and is randomised, double-blind and placebo-controlled. The independence test the literature has largely lacked.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and reviewed by

William Heath · Editor, UK Peptides research library

William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.

More BPC-157 (Pentadecapeptide) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.